Trial Profile
A retrospective study evaluating efficacy of 177Lu-DOTATATE in patients with metastatic or unresectable neuroendocrine tumors
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Aug 2016
Price :
$35
*
At a glance
- Drugs Lutetium-(177Lu)-oxodotreotide (Primary)
- Indications Neuroendocrine tumours
- Focus Therapeutic Use
- 09 Aug 2016 New trial record